ReviewAlzheimer's research & therapy2017
Study partners should be required in preclinical Alzheimer's disease trials.
Review in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.Alzheimer's research & therapy · 2018Pooled it
- Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.The journal of prevention of Alzheimer's disease · 2024Trial
- "Like Taking Part in Star Wars": Qualitative Study Using Thematic Analysis to Explore the Acceptability and Experiences of Older Adults Participating in Remote Longitudinal Sleep and Dementia Research.Journal of medical Internet research · 2026Article
- Characterizing the Research Participant Recruitment Funnel for Alzheimer's Secondary Prevention Trials: Results from A National Survey of U.S. Adults.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2025Article
- Longitudinal Remote Sleep and Cognitive Research in Older Adults With Mild Cognitive Impairment and Dementia: Prospective Feasibility Cohort Study.JMIR aging · 2025Article
- Study partner characteristics moderate the prediction of cognitive decline in aging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Advancing Aging Research Through a Health Disparities Perspective.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Brain Health Registry Study Partner Portal: Novel infrastructure for digital, dyadic data collection.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.The journal of prevention of Alzheimer's disease · 2024Article
- Caregivers in implantable brain-computer interface research: a scoping review.Frontiers in human neuroscience · 2024Article
- Gender of Study Partners and Research Participants Associated With Differences in Study Partner Ratings of Cognition and Activity Level.The journals of gerontology. Series B, Psychological sciences and social sciences · 2023Article
- Designing Inclusive Qualitative Research with Carers of People Living with Dementia: Methodological Insights.Healthcare (Basel, Switzerland) · 2023Article
- Retention of Study Partners in Longitudinal Studies of Alzheimer Disease.Journal of Alzheimer's disease : JAD · 2023Article
- US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.The journal of prevention of Alzheimer's disease · 2023Article
- Recruiting Persons with Dementia and Caregivers in a Clinical Trial: Dyads Perceptions.Western journal of nursing research · 2022Article
- Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimer's Disease.Neurochemical research · 2022Review
- Robust EEG Based Biomarkers to Detect Alzheimer's Disease.Brain sciences · 2021Article
- Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?The journal of prevention of Alzheimer's disease · 2021Article
- Informed consent, therapeutic misconception, and clinical trials for Alzheimer's disease.International journal of geriatric psychiatry · 2020Article
- Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's trials.Alzheimer's research & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundIn an effort to intervene earlier in Alzheimer's disease (AD), clinical trials are testing promising candidate therapies in preclinical disease. Preclinical AD trial participants are cognitively normal, functionally independent, and autonomous decision-makers. Yet, like AD dementia trials, preclinical trials require dual enrollment of a participant and a knowledgeable informant, or study partner. MAIN TEXT: The requirement of dyadic enrollment is a barrier to recruitment and may present unique ethical challenges. Despite these limitations, the requirement should continue. Study partners may be essential to ensure participant safety and wellbeing, including overcoming distress related to biomarker disclosure and minimizing risk for catastrophic reactions and suicide. The requirement may maximize participant retention and ensure data integrity, including that study partners are the source of data that will ultimately instruct whether a new treatment has a clinical benefit and meaningful impact on the population health burden associated with AD. Finally, study partners are needed to ensure the scientific and clinical value of trials.
conclusionsPreclinical AD will represent a new model of care, in which persons with no symptoms are informed of probable cognitive decline and eventual dementia. The rationale for early diagnosis in symptomatic AD is equally applicable in preclinical AD-to minimize risk, maximize quality of life, and ensure optimal planning and communication. Family members and other sources of support will likely be essential to the goals of this new model of care for preclinical AD patients and trials must instruct this clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.